Wednesday, July 8, 2026

Patent intelligence · US

US 9604976

Antibacterial compounds

granted A61PA61P11/00A61P15/00A61P17/00
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 11
Applicant portfolio 16
Patent details — US 9604976
Jurisdiction
US
Status
granted
Grant date
Mar 28, 2017
Expiration
Mar 23, 2037
Applicant
SPERO GYRASE, INC.
Claims
16
CPC classes
A61P, A61P11/00, A61P15/00, A61P17/00
View on Google Patents ↗

Quick answer

US 9604976 (Antibacterial compounds) is held by SPERO GYRASE, INC.. Status: granted. Granted Mar 28, 2017. Expires Mar 23, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Applicant
SPERO GYRASE, INC.
Grant date
Expiration
Claims
16
CPC classes
A61P, A61P11/00, A61P15/00, A61P17/00, A61P31/04, A61P7/00

More from SPERO GYRASE, INC.

Related pharmaceutical patents in our USPTO index.

  1. US 12428395

    Heterocyclic compounds as kinase inhibitor and uses thereof

    SPEROGENIX THERAPEUTICS LIMITED · Expires Sep 25, 2045

    granted
  2. US 12291548

    Compounds, compositions, and methods for the treatment of disease

    Sperovie Biosciences, Inc. · Expires May 1, 2045

    granted
  3. US 12226403

    Tebipenem pivoxil immediate and modified release oral dosage forms

    SPERO THERAPEUTICS, INC. · Expires Feb 13, 2045

    granted
  4. US 12146004

    Polymyxin compounds and uses thereof

    SPERO THERAPEUTICS, INC. · Expires Nov 14, 2044

    granted
  5. US 12098155

    Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use

    SPERO THERAPEUTICS, INC. · Expires Sep 19, 2044

    granted
  6. US 12048691

    High dosage tebipenem pivoxil tablet formulation

    SPERO THERAPEUTICS, INC. · Expires Jul 25, 2044

    granted
  7. US 11718621

    Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use

    SPERO THERAPEUTICS, INC. · Expires Aug 3, 2043

    granted
  8. US 11459357

    Polymyxin compounds

    SPERO THERAPEUTICS, INC. · Expires Sep 29, 2042

    granted

Frequently asked questions

What is US patent 9604976?

US 9604976 (Antibacterial compounds) is held by SPERO GYRASE, INC.. Status: granted. Granted Mar 28, 2017. Expires Mar 23, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 9604976?

SPERO GYRASE, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 16 pharmaceutical patents for this assignee.

When does US 9604976 expire?

Our index shows an expiration date of Mar 23, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.